Skip to content
Companies

RLL Bio

Oral drug that blocks cancer cell DNA repair and growth

Raised to date

$2M

across 1 Form D filing

Investors
11
Last filed
Apr 6, 2026

About

RLL is a clinical-stage biopharmaceutical company in Lutherville, Maryland developing novel cancer therapeutics. Its lead asset, AOH1996, is a first-in-class oral small molecule that binds a central driver of cancer cell proliferation to block tumor growth, DNA repair, and replication while reportedly leaving normal cells largely unaffected. AOH1996 is in Phase 1 clinical trials, and the company also maintains a veterinary pipeline. RLL was co-founded by breast surgical oncologist Dr. Lauren Schnaper, who serves as president.

AOH1996 has a first-in-class mechanism that targets a protein central to cancer cell proliferation, showing high selectivity for cancer over normal cells, low reported toxicity, synergy with existing chemotherapies at lower doses, and resistance to the escape pathways tumors typically develop.

Funding

  • Security to be acquiredFiled Apr 6, 2026Form D
    $2M/ no target

Product

AOH1996

Oncology drug candidate (clinical stage)

A first-in-class oral small-molecule anticancer drug candidate that binds a central driver of cancer cell proliferation, blocking cancer cell growth, DNA repair, and replication.

  • Oral administration
  • First-in-class mechanism of action against a central proliferation driver
  • High selectivity for cancer cells with low-to-no reported toxicity

Built for

Oncology patients and their treating clinicians, reached through the pharmaceutical development pathway; veterinary oncology as a secondary program.

People on file